Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Harrow Health Inc.

    NASDAQ: HROW · Real-Time Price · USD
    31.53
    1.22 (4.03%)
    At close: Jun 16, 2025, 3:59 PM
    31.70
    0.54%
    After-hours: Jun 16, 2025, 06:37 PM EDT
    4.03%
    Bid 30
    Market Cap 1.16B
    Revenue (ttm) 212.86M
    Net Income (ttm) -21.7M
    EPS (ttm) -0.61
    PE Ratio (ttm) -51.69
    Forward PE 20.11
    Analyst Strong Buy
    Ask 34
    Volume 303,495
    Avg. Volume (20D) 555,344
    Open 30.85
    Previous Close 30.31
    Day's Range 30.02 - 31.63
    52-Week Range 16.87 - 59.23
    Beta 0.40

    About HROW

    undefined

    [Read more]
    Industry n/a
    Sector n/a
    IPO Date n/a
    Employees NaN
    Stock Exchange n/a
    Ticker Symbol HROW
    Website n/a
    Full Company Profile

    Analyst Forecast

    According to 0 analyst ratings, the average rating for HROW stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

    Stock Forecasts

    Why Price Moved

    Why Price Moved is a one-sentence explanation of why a stock is moving higher or down. By removing noise and collecting signals from news, press releases and SEC filings, we can pinpoint the trigger for price movements.
    1 month ago
    +3.43%
    HROW stock has given up its prior loss. Harrow sha... Unlock content with Pro Subscription
    1 month ago
    +3.43%
    Harrow shares are trading lower after the company reported worse-than-expected Q1 financial results.
    news image

    4 days ago · seekingalpha.com

    I Am Swimming In Dividends With +7% Yields

    Winning in gold requires patience and a steady strategy to use the environment to your advantage. The same holds true for investing. Focus on steady dividends over chasing market hype or short-term ga...

    news image

    1 week ago · businesswire.com

    Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

    NASHVILLE, Tenn. & TAIPEI, Taiwan--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838....

    news image

    2 weeks ago · seekingalpha.com

    Harrow: Epic Growth & Operating Leverage On Full Display

    Harrow has successfully leveraged its compounding pharmacy roots to drive rapid branded drug growth. Revenue has grown at a steady 40% CAGR for a decade & EBITDA has grown even more sharply. Managemen...

    news image

    1 month ago · businesswire.com

    Harrow to Present at Two Investor Conferences in May

    NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that management will participate in the following two inves...

    news image

    1 month ago · seekingalpha.com

    Harrow, Inc. (HROW) Q1 2025 Earnings Call Transcript

    Harrow, Inc. (NASDAQ:HROW ) Q1 2025 Results Conference Call May 9, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Par...

    news image

    1 month ago · zacks.com

    Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates

    Harrow (HROW) came out with a quarterly loss of $0.38 per share versus the Zacks Consensus Estimate of $0.02. This compares to loss of $0.28 per share a year ago.

    news image

    1 month ago · businesswire.com

    Harrow to Report First Quarter 2025 Financial Results After Market Close on May 8, 2025

    NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it will report its financial results for the first qua...

    news image

    1 month ago · seekingalpha.com

    What Recession? I'm Swimming In Dividends

    What Recession? I'm Swimming In Dividends

    news image

    2 months ago · businesswire.com

    Harrow Expands VEVYE® Access for All Program to ImprimisRx's Klarity-C Patients

    NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced an expansion of its VEVYE® Access for All (“VAFA”) program ...

    news image

    2 months ago · seekingalpha.com

    Harrow: When Cheaper Doesn't Mean Attractive (Rating Upgrade)

    Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex reimbur...

    Add to Watchlist